Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
2.015 USD | +6.05% | +5.76% | -32.44% |
03-25 | Esperion Shares Continue Rise After Friday's FDA Approval for Nexlizet, Nexletol | DJ |
03-25 | Sector Update: Health Care Stocks Steady Premarket Monday | MT |
Sales 2024 * | 265M 362M | Sales 2025 * | 406M 554M | Capitalization | 360M 491M |
---|---|---|---|---|---|
Net income 2024 * | -69M -94.23M | Net income 2025 * | 60M 81.94M | EV / Sales 2024 * | 1.36 x |
Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | 0.89 x |
P/E ratio 2024 * |
-4.71
x | P/E ratio 2025 * |
10.2
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 98.51% |
Latest transcript on Esperion Therapeutics, Inc.
1 day | +6.05% | ||
1 week | +5.76% | ||
Current month | -24.63% | ||
1 month | -27.60% | ||
3 months | -6.91% | ||
6 months | +144.46% | ||
Current year | -32.44% |
Managers | Title | Age | Since |
---|---|---|---|
Sheldon Koenig
CEO | Chief Executive Officer | 58 | 20-12-14 |
Director of Finance/CFO | 38 | 19-12-31 | |
JoAnne Foody
CTO | Chief Tech/Sci/R&D Officer | 59 | 21-06-27 |
Members of the board | Title | Age | Since |
---|---|---|---|
Director/Board Member | 52 | 22-04-27 | |
J. Carroll
CHM | Chairman | 74 | 22-05-31 |
Alan Fuhrman
BRD | Director/Board Member | 67 | 20-03-15 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.02% | 237 M€ | +3.42% | - | |
0.00% | 2 M€ | -.--% |
Date | Price | Change | Volume |
---|---|---|---|
24-04-29 | 2.015 | +6.05% | 2 927 756 |
24-04-26 | 1.9 | -4.52% | 4,198,930 |
24-04-25 | 1.99 | -6.57% | 5,147,052 |
24-04-24 | 2.13 | +1.91% | 5,684,029 |
24-04-23 | 2.09 | +9.42% | 4,946,560 |
Delayed Quote Nasdaq, April 29, 2024 at 02:16 pm
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-32.44% | 360M | |
+25.93% | 661B | |
+26.74% | 566B | |
-6.65% | 352B | |
+19.38% | 332B | |
+3.37% | 283B | |
+13.43% | 231B | |
+4.71% | 200B | |
-9.53% | 195B | |
-4.15% | 145B |
- Stock Market
- Equities
- ESPR Stock